Inside the tactical tug of war over the controversial Alzheimer's drug

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the decision to pay only for patients taking the drug in a clinical trial.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Switzerland ,Tufts Medical Center ,New Yorker ,Americans ,Swiss ,Joseph Ross ,Cathy Mcmorris Rodgers ,Adriane Fugh Berman ,Robert Egge ,Jim Taylor ,National Minority Quality Forum ,Yale University ,More Perfect Union ,Centers For Medicare Medicaid Services ,Genentech ,Commerce Committee ,Kaiser Family Foundation ,House Energy ,Georgetown University ,Kaiser Health News ,Alzheimer Association ,Cleveland Clinic ,Johns Hopkins Hospital ,Massachusetts General ,Medicaid Services ,Sean Tunis ,Policy Analysis ,